TDM 180935
Alternative Names: TDM-180935; TDM-Atop01Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator TechnoDerma Medicines
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 06 Jan 2025 Efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Technoderma Medicines
- 31 Dec 2024 Technoderma Medicines completes a phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT06363461)
- 13 Apr 2024 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT06363461)